The stock of Ultragenyx Pharmaceutical Inc (RARE) has seen a 2.46% increase in the past week, with a 3.93% gain in the past month, and a -6.90% decrease in the past quarter. The volatility ratio for the week is 0.71%, and the volatility levels for the past 30 days are at 2.38% for RARE. The simple moving average for the past 20 days is 4.33% for RARE’s stock, with a -16.09% simple moving average for the past 200 days.
Is It Worth Investing in Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Right Now?
The 36-month beta value for RARE is also noteworthy at 0.25. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 6 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for RARE is 88.37M, and at present, short sellers hold a 6.28% of that float. The average trading volume of RARE on June 12, 2025 was 946.54K shares.
RARE) stock’s latest price update
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)’s stock price has plunge by 0.00relation to previous closing price of 37.51. Nevertheless, the company has seen a 2.46% surge in its stock price over the last five trading sessions. zacks.com reported 2025-06-05 that Ultragenyx (RARE) reported earnings 30 days ago. What’s next for the stock?
Analysts’ Opinion of RARE
Goldman, on the other hand, stated in their research note that they expect to see RARE reach a price target of $67, previously predicting the price at $56. The rating they have provided for RARE stocks is “Buy” according to the report published on June 06th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to RARE, setting the target price at $77 in the report published on April 22nd of the previous year.
RARE Trading at 4.85% from the 50-Day Moving Average
After a stumble in the market that brought RARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.87% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at RARE starting from Crombez Eric, who sale 520 shares at the price of $39.24 back on May 05 ’25. After this action, Crombez Eric now owns 71,530 shares of Ultragenyx Pharmaceutical Inc, valued at $20,405 using the latest closing price.
Crombez Eric, the EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc, sale 242 shares at $35.11 during a trade that took place back on Apr 21 ’25, which means that Crombez Eric is holding 71,680 shares at $8,497 based on the most recent closing price.
Stock Fundamentals for RARE
Current profitability levels for the company are sitting at:
- -0.87 for the present operating margin
- 0.84 for the gross margin
The net margin for Ultragenyx Pharmaceutical Inc stands at -0.93. The total capital return value is set at -0.5. Equity return is now at value -386.33, with -41.97 for asset returns.
Based on Ultragenyx Pharmaceutical Inc (RARE), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -10.19. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -8.35.
Currently, EBITDA for the company is -469.0 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 5.85. The receivables turnover for the company is 5.98for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.40.
Conclusion
In summary, Ultragenyx Pharmaceutical Inc (RARE) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
